FGF21 gene therapy as treatment for obesity and insulin resistance

FGF21 gene therapy as treatment for obesity and insulin resistance

Abstract Prevalence of type 2 diabetes (T2D) and obesity is increasing worldwide. Currently available therapies are not suited for all patients in the heterogeneous obese/T2D population, hence the need for novel treatments. Fibroblast growth factor 21 (FGF21) is considered a promising therapeutic ag...

Full description

Bibliographic Details
Main Authors: Veronica Jimenez, Claudia Jambrina, Estefania Casana, Victor Sacristan, Sergio Muñoz, Sara Darriba, Jordi Rodó, Cristina Mallol, Miquel Garcia, Xavier León, Sara Marcó, Albert Ribera, Ivet Elias, Alba Casellas, Ignasi Grass, Gemma Elias, Tura Ferré, Sandra Motas, Sylvie Franckhauser, Francisca Mulero, Marc Navarro, Virginia Haurigot, Jesus Ruberte, Fatima Bosch
Format: Article
Language:English
Published: Springer Nature 2018-08-01
Series:EMBO Molecular Medicine
Subjects:
AAV gene therapy
FGF21
insulin resistance
obesity
type 2 diabetes
Online Access:https://doi.org/10.15252/emmm.201708791

Internet

https://doi.org/10.15252/emmm.201708791

Similar Items